EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Beam Therapeutics's enterprise value is $671.78 Mil.
Beam Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $63.58 Mil. Therefore, Beam Therapeutics's EV-to-Revenue for today is 10.57.
The historical rank and industry rank for Beam Therapeutics's EV-to-Revenue or its related term are showing as below:
BEAM'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.25 Med: 19.34 Max: 6950.67
Current: 10.57
During the past 8 years, the highest EV-to-Revenue of Beam Therapeutics was 6950.67. The lowest was 2.25. And the median was 19.34.
BEAM's EV-to-Revenue is ranked worse than 58.05% of 994
companies
in the Biotechnology industry
Industry Median: 7.16
vs BEAM: 10.57
The historical data trend for Beam Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beam Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Beam Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's EV-to-Revenue falls into.
Beam Therapeutics's current Enterprise Value is $671.78 Mil.
Beam Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $63.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics's share price for today is $16.83.
Beam Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.76.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Beam Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BEAM has been successfully added to your 